POS1210 SAFETY AND IMMUNOGENICITY OF COVID-19 VACCINES IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASE
Authors: C. Hitchon, R. Marrie, C. N. Bernstein, J. Kim, S. Obrien
Journal: Annals of the Rheumatic Diseases (2022)

Background COVID-19 vaccination strategies have evolved with increasing vaccine availability and emerging vaccine safety data. While data on immunogenicity and safety of COVID vaccination strategies exists, there is limited data for people with immune mediated inflammatory diseases (IMIDs) such as inflammatory arthritis (IA), systemic autoimmune rheumatic disease (SARD), inflammatory bowel disease (IBD) and multiple sclerosis (MS). Objectives In IMID patients treated with homologous or heterogeneous COVID vaccines, to compare post vaccine IMID disease activity and COVID antibody responses. Methods Between March 2021 and Dec 2021, patients with IA (n= 70; 77% rheumatoid arthritis), SARD (n=82; 70% lupus), IBD (n= 92; 40% crohn’s), and MS (n= 71; 77% RRMS) self-reported COVID illness and exposure risks, and disease activity prior to and 1 month post both COVID-19 vaccinations (V1 and V2). Disease activity was assessed by the Systemic Lupus Activity Questionnaire (SLAQ) for SARDs, the RAPID-3 and RA flate index for IA, the IBD Symptoms Inventory-short form (IBDSI) and IBD flare index for IBD and the 25 meter walk and 9 hole peg test and Expanded Disability Status Scale (EDSS) for MS. Patient reported flare state was assessed using the relevant questions these indices (SLAQ “Have you had a flare?”; RA Flare index “Are you in a flare?”; IBD flare “My IBD is sometimes to continously active“). Disease activity and serum anti-spike, anti-receptor binding domain (RBD) and anti-nucleocapsid (NC) IgG antibody titers at 30 days post V2 were compared across vaccine courses and to age-sex matched vaccinated blood donor controls (CNTS). Results Patients were predominantly female (79.7%), with a mean (standard deviation-sd) age of 56 (15) years; 8% had suspected or diagnosed COVID-19 illness; 1.2% positive anti-NC (Table 1). For all IMIDS, the majority received mRNA vaccines-BNT162b2 (BNT) or mRNA1273 (V1 74%; V2 97%;) the rest received ChAdOx1 viral vector vaccines; 71% received homologogous vaccines (ChAdOx1-ChAdOx n=6; BNT-BNT n=174; mRNA1271-mRNA1273 n=21; ChAdOx1-BNT n=36; ChAdOx1- mRNA1273 n=30; BNT-mRNA1273 n=15; mRNA1273-BNT n=3; other n=4). For most IMIDs, disease activity was similar before and after each vaccination. Post V2 disease activity did not differ between homologous versus heterologous vaccines nor by vaccine type (RAPID3; SLAQ, 25 meter walk and 9 hole peg test and EDSS overall and subscales, IBDSI overall and subscales all p=NS). In 254 IMIDs, most seroconverted (anti-spike 86%; anti-RBD 96%). Seroconversion rates for CNTS were 98.1% for anti-Spike and 3.5% for anti-NC. Antibody titers were higher following homologous mRNA (BNT or mRNA12723) than homologous vector vaccine (Figure 1). For IMIDs primed with ChAdOx vector vaccine, boosting with BNT or mRNA1273 generated similarly increased anti-Spike and anti-RBD titers. Table 1. All IMIDs IA SARD IBD MS Age (mean (sd) years ) 56(15 ) 63(12 ) 56(14 ) 54(16 ) 51(17 ) Female (% ) 80 84 90 64 83 COVID risk exposure (% ) Any 44 39 46 50 44 Contact 14 12 14 12 21 Travel 6 6 6 6 6 HCW/hospitalized 15 15 16 20 9 Other risk 9 6 10 12 8 V1 mRNA (% ) 74 80 68 82 64 V2 mRNA (% ) 97 98 96 96 99 Homologous V1 V2 (% ) 71 79 67 74 64 Flare status post V2 (% ) 10 15 6 0 - Seroconversion (% ) Anti-Spike 89 90 86 93 84 Anti-RBD 91 92 86 96 88 Figure 1. Post vaccine antibody titers Conclusion Heterologous COVID vaccination improves seroconversion rates following a viral vector vaccine and does not lead to disease flare in most IMID patients. While data is needed to assess vaccine effectiveness, duration of immunogenicity and effects of subsequent vaccination, this work supports mixing COVID vaccines for IMID patients. Acknowledgements Study funded by Research Manitoba Disclosure of Interests None declared